A Flea-Associated Rickettsia Pathogenic for Humans
A rickettsia named the ELB agent, or "Rickettsia felis," was identified by molecular biology techniques in American fleas in 1990 and later in four patients from Texas and Mexico. We attempted to isolate this rickettsia from infected fleas at various temperatures and conditions. A represen...
Main Authors: | , , , , , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
Centers for Disease Control and Prevention
2001-02-01
|
Series: | Emerging Infectious Diseases |
Subjects: | |
Online Access: | https://wwwnc.cdc.gov/eid/article/7/1/70-0073_article |
id |
doaj-180809cbe9814d5b8bb3d96918e1285d |
---|---|
record_format |
Article |
spelling |
doaj-180809cbe9814d5b8bb3d96918e1285d2020-11-24T21:11:53ZengCenters for Disease Control and PreventionEmerging Infectious Diseases1080-60401080-60592001-02-0171738110.3201/eid0701.700073A Flea-Associated Rickettsia Pathogenic for HumansDidier RaoultBernard La ScolaMaryse EneaPierre-Edouard FournierVéronique RouxFlorence FenollarMarcio A.M. GalvaoXavier de LamballerieA rickettsia named the ELB agent, or "Rickettsia felis," was identified by molecular biology techniques in American fleas in 1990 and later in four patients from Texas and Mexico. We attempted to isolate this rickettsia from infected fleas at various temperatures and conditions. A representative isolate of the ELB agent, the Marseille strain, was characterized and used to develop a microimmunofluorescence test that detected reactive antibodies in human sera. The ELB agent was isolated from 19 of 20 groups of PCR-proven infected fleas. The microimmunofluorescence results provided serologic evidence of infection by the ELB agent in four patients with fever and rash in France (2) and Brazil (2), supporting the pathogenic role of this rickettsia. Our successful isolation of this rickettsia makes it available for use in serologic tests to determine its clinical spectrum, prevalence, and distribution.https://wwwnc.cdc.gov/eid/article/7/1/70-0073_articleBrazilFrance |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
Didier Raoult Bernard La Scola Maryse Enea Pierre-Edouard Fournier Véronique Roux Florence Fenollar Marcio A.M. Galvao Xavier de Lamballerie |
spellingShingle |
Didier Raoult Bernard La Scola Maryse Enea Pierre-Edouard Fournier Véronique Roux Florence Fenollar Marcio A.M. Galvao Xavier de Lamballerie A Flea-Associated Rickettsia Pathogenic for Humans Emerging Infectious Diseases Brazil France |
author_facet |
Didier Raoult Bernard La Scola Maryse Enea Pierre-Edouard Fournier Véronique Roux Florence Fenollar Marcio A.M. Galvao Xavier de Lamballerie |
author_sort |
Didier Raoult |
title |
A Flea-Associated Rickettsia Pathogenic for Humans |
title_short |
A Flea-Associated Rickettsia Pathogenic for Humans |
title_full |
A Flea-Associated Rickettsia Pathogenic for Humans |
title_fullStr |
A Flea-Associated Rickettsia Pathogenic for Humans |
title_full_unstemmed |
A Flea-Associated Rickettsia Pathogenic for Humans |
title_sort |
flea-associated rickettsia pathogenic for humans |
publisher |
Centers for Disease Control and Prevention |
series |
Emerging Infectious Diseases |
issn |
1080-6040 1080-6059 |
publishDate |
2001-02-01 |
description |
A rickettsia named the ELB agent, or "Rickettsia felis," was identified by molecular biology techniques in American fleas in 1990 and later in four patients from Texas and Mexico. We attempted to isolate this rickettsia from infected fleas at various temperatures and conditions. A representative isolate of the ELB agent, the Marseille strain, was characterized and used to develop a microimmunofluorescence test that detected reactive antibodies in human sera. The ELB agent was isolated from 19 of 20 groups of PCR-proven infected fleas. The microimmunofluorescence results provided serologic evidence of infection by the ELB agent in four patients with fever and rash in France (2) and Brazil (2), supporting the pathogenic role of this rickettsia. Our successful isolation of this rickettsia makes it available for use in serologic tests to determine its clinical spectrum, prevalence, and distribution. |
topic |
Brazil France |
url |
https://wwwnc.cdc.gov/eid/article/7/1/70-0073_article |
work_keys_str_mv |
AT didierraoult afleaassociatedrickettsiapathogenicforhumans AT bernardlascola afleaassociatedrickettsiapathogenicforhumans AT maryseenea afleaassociatedrickettsiapathogenicforhumans AT pierreedouardfournier afleaassociatedrickettsiapathogenicforhumans AT veroniqueroux afleaassociatedrickettsiapathogenicforhumans AT florencefenollar afleaassociatedrickettsiapathogenicforhumans AT marcioamgalvao afleaassociatedrickettsiapathogenicforhumans AT xavierdelamballerie afleaassociatedrickettsiapathogenicforhumans AT didierraoult fleaassociatedrickettsiapathogenicforhumans AT bernardlascola fleaassociatedrickettsiapathogenicforhumans AT maryseenea fleaassociatedrickettsiapathogenicforhumans AT pierreedouardfournier fleaassociatedrickettsiapathogenicforhumans AT veroniqueroux fleaassociatedrickettsiapathogenicforhumans AT florencefenollar fleaassociatedrickettsiapathogenicforhumans AT marcioamgalvao fleaassociatedrickettsiapathogenicforhumans AT xavierdelamballerie fleaassociatedrickettsiapathogenicforhumans |
_version_ |
1716752374698082304 |